Hot Features
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardio... Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors. In addition, the company develops LX9851, an orally-delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders, and pilavapadin (LX9211), an orally-delivered small molecule drug candidate for the treatment of neuropathic pain. It has strategic collaboration and license agreements with Viatris Inc. and Bristol-Myers Squibb Company. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.25 | -11.5207373272 | 2.17 | 2.185 | 1.8 | 2232134 | 1.91470429 | CS |
| 4 | -0.09 | -4.4776119403 | 2.01 | 2.53 | 1.8 | 2983742 | 2.20180805 | CS |
| 12 | 0.215 | 12.6099706745 | 1.705 | 2.53 | 1.49 | 2453700 | 1.89802523 | CS |
| 26 | 0.5 | 35.2112676056 | 1.42 | 2.53 | 1.1 | 2541787 | 1.62570825 | CS |
| 52 | 1.15 | 149.350649351 | 0.77 | 2.53 | 0.635 | 2687360 | 1.37497185 | CS |
| 156 | -1.06 | -35.5704697987 | 2.98 | 3.73 | 0.2836 | 4074663 | 1.20404276 | CS |
| 260 | -2.97 | -60.736196319 | 4.89 | 6.3299 | 0.2836 | 2803344 | 1.46085793 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.